<DOC>
	<DOCNO>NCT00005665</DOCNO>
	<brief_summary>We hypothesize ingested human recombinant interferon-alpha ( hrIFN-a ) prolong `` honeymoon '' period enhance B cell survival type 1 diabetes phase II randomize , placebo-controlled , double-blind clinical trial . We demonstrate ingested IFN-a prevents type 1 diabetes NOD mouse , prolongs `` honeymoon '' period newly diagnose type 1 diabetic , delay murine islet allograft rejection . The natural history type 1 diabetes unique phase frequently refer `` honeymoon , '' period insulin need becomes minimal glycemic control improve . The B cell ( insulin produce cell ) partially recovers . However , honeymoon , end patient becomes completely insulin-deficient . The general consensus international diabetes community test potential preventive therapy type 1 diabetes newly diagnose patient . Prolongation honeymoon reversal disease consider positive result . In phase II randomize , double-blind , parallel-design clinical trial determine whether ingest ( oral ) human recombinant IFN-a prolong `` honeymoon '' period increase counterregulatory anti-inflammatory cytokine ( ) . We determine safety efficacy 30,000 unit ingest hrIFN-a v placebo eighty patient newly diagnose type 1 diabetes phase II trial one year . Primary outcome measure 30 % increase C-peptide level release Sustacal stimulation 3 , 6 , 9 , 12 month entry . Secondary outcome decrease titer islet cell antibody ( ICA ) . If successful , large long phase III trial prevention type 1 diabetes high risk patient undertaken . We also determine ingested hrIFN-a increase IL-4 , IL-10 IFN-a production peripheral blood mononuclear cell ( PMNC ) patient recent onset type 1 diabetes .</brief_summary>
	<brief_title>Ingested Interferon Alpha : Prolongation Permanence `` Honeymoon '' Phase Newly Diagnosed Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Newly diagnose type 1 diabetes ( within one month diagnosis ) . IDDM patient : Prepubescent , adolescent , early adult patient . Patients age 3 25 . Patients eligible immunosuppressive immunostimulatory medication azathioprine , oral nicotinamide , superoxide dismutasedesferroxamine , vitamin E , aminoguanidine , oral insulin experimental therapy time . Patients history alcoholism , renal , cardiac , pulmonary disease intellectual functioning impair sufficiently interfere understand protocol , participation treatment evaluation program Patients pregnant nursing , willing practice acceptable birth control method Patients abnormal pretreatment value WBC receive potentially hepatotoxic medication</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>